Neogen reported first-quarter fiscal 2027 revenue of $222.8 million, up 6.5% from a year earlier, and raised its fiscal 2027 revenue and Adjusted EBITDA guidance. The company still posted a GAAP net loss of $11.9 million, compared with net income of $36.3 million a year earlier, when a $76.4 million gain on the sale of a business boosted results.
Revenue of $222.8 million vs. $209.2 million a year earlier; core revenue growth of 8.1%
Net loss of $11.9 million, or $(0.05) per diluted share, vs. net income of $36.3 million, or $0.17, a year earlier; Adjusted EPS was $0.08 vs. $0.04
Fiscal 2027 revenue guidance raised to $885 million to $890 million from $880 million to $885 million; Adjusted EBITDA guidance raised to $181 million to $183 million from $180 million to $182 million
Pending sale of the Genomics business to Zoetis Inc. is expected to conclude regulatory reviews by the end of December 2026
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Neogen's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2026
$870.40M
-2.7%
$-0.04
—
-0.9%
FY2025
$894.70M
-3.2%
$-5.03
—
-122.1%
FY2024
$924.20M
+12.4%
$-0.04
—
-1.0%
FY2023
$822.45M
+56.0%
$-0.12
-126.7%
-2.8%
FY2022
$527.16M
+12.5%
$0.45
-21.1%
9.2%
Frequently asked questions
When is Neogen's next earnings date?
Neogen has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Neogen earn last quarter?
For the quarter ended Aug 2026, Neogen reported diluted EPS of $-0.05 (-129.4% year over year) on revenue of $222.80M (+6.5%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.